Waters Corporation $WAT Holdings Raised by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. lifted its position in shares of Waters Corporation (NYSE:WAT) by 19.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,299 shares of the medical instruments supplier’s stock after acquiring an additional 1,812 shares during the period. Crossmark Global Holdings Inc.’s holdings in Waters were worth $4,292,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in WAT. Exencial Wealth Advisors LLC increased its stake in Waters by 1.7% during the fourth quarter. Exencial Wealth Advisors LLC now owns 1,681 shares of the medical instruments supplier’s stock valued at $638,000 after purchasing an additional 28 shares during the last quarter. Rosenberg Matthew Hamilton raised its holdings in shares of Waters by 8.8% during the fourth quarter. Rosenberg Matthew Hamilton now owns 359 shares of the medical instruments supplier’s stock worth $136,000 after purchasing an additional 29 shares during the period. Integrated Wealth Concepts LLC lifted its position in shares of Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after buying an additional 30 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC lifted its position in shares of Waters by 1.8% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,751 shares of the medical instruments supplier’s stock worth $665,000 after buying an additional 31 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in shares of Waters by 8.7% in the 4th quarter. Signaturefd LLC now owns 411 shares of the medical instruments supplier’s stock valued at $156,000 after buying an additional 33 shares during the period. 94.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on WAT. Wells Fargo & Company lowered their price objective on shares of Waters from $415.00 to $355.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 11th. TD Cowen lifted their target price on Waters from $345.00 to $385.00 and gave the company a “hold” rating in a research note on Wednesday. Robert W. Baird set a $387.00 target price on Waters in a research note on Wednesday. Evercore upgraded Waters from an “in-line” rating to an “outperform” rating and set a $350.00 price target on the stock in a research report on Monday, April 6th. Finally, HSBC started coverage on Waters in a report on Tuesday, January 27th. They issued a “buy” rating and a $460.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Waters presently has an average rating of “Moderate Buy” and an average price target of $395.12.

Waters Price Performance

Shares of NYSE:WAT opened at $355.12 on Monday. The stock has a market cap of $34.86 billion, a price-to-earnings ratio of 45.12, a PEG ratio of 2.24 and a beta of 1.14. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.71 and a quick ratio of 0.43. Waters Corporation has a 12 month low of $275.05 and a 12 month high of $414.15. The stock’s 50 day moving average price is $310.84 and its 200 day moving average price is $352.26.

Waters (NYSE:WAT) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.31 by $0.39. Waters had a return on equity of 15.60% and a net margin of 11.91%.The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same period last year, the firm earned $2.25 EPS. The firm’s revenue for the quarter was up 91.4% on a year-over-year basis. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Equities research analysts anticipate that Waters Corporation will post 14.49 earnings per share for the current fiscal year.

Insider Transactions at Waters

In other news, Director Wei Jiang bought 500 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were purchased at an average cost of $289.46 per share, with a total value of $144,730.00. Following the completion of the acquisition, the director directly owned 3,441 shares in the company, valued at approximately $996,031.86. The trade was a 17.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.31% of the stock is currently owned by insiders.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.